Engine Biosciences Valuation, Funding & Investors
Engine Biosciences is valued at $82M as of July 2023.
Last Engine Biosciences valuation
$82M
Series A · Jul 2023
Last Engine Biosciences funding round
$5M
Undisclosed stage · Aug 2026
Cumulative funding Engine Biosciences raised
$122M
across 8 funding rounds
Key investors in Engine Biosciences
EDBI
Polaris Partners
Invus
Baidu Ventures
DHVC
WI Harper Group
About Engine Biosciences
Engine Biosciences is a San Francisco- and Singapore-headquartered biotechnology firm leveraging AI and network biology for drug discovery and cellular reprogramming. The company combines wet-lab high-throughput screening with machine learning algorithms to map biological networks, accelerating therapies for cancer, fibrosis, and neurodegenerative diseases. Founded in 2018 by scientists from MIT, Harvard, Mayo Clinic, and UCSD, Engine Biosciences partners with pharma giants like Novartis and Takeda, maintaining labs in Asia and the US with ongoing clinical candidates.
Founded
2014
HQ
SingaporeWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$82M (Jul 2023)
Engine Biosciences Valuation
Engine Biosciences is currently valued at $82M, based on its Series A in July 2023.
The $18M round included Polaris Partners and EDBI.
Engine Biosciences valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jul 2023 | Series A | $82M |
Engine Biosciences Funding History
Engine Biosciences has raised a total of $122M across 8 funding rounds.
Engine Biosciences' first fundraising round was a $10M seed round in January 2018. The most recent completed round was a $5M undisclosed-stage round in August 2026.
Engine Biosciences funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Aug 2026 | Undisclosed stage | GV (lead) | $5M | - | Alphabet’s venture capital arm, GV, invested $5 million in Engine Biosciences in August 2026. The transaction came shortly after a nearly $7.5 million investment from Pfizer Ventures and followed a prior $13.6 million financing earlier in 2026, reflecting continued investor support for the company’s oncology-focused drug discovery platform. Engine Biosciences is a Singapore-based biotechnology company using artificial intelligence and machine learning with high-throughput biology to discover precision oncology medicines and biomarkers for patient selection. The company was founded to combine wet-lab experimentation and computational methods for drug discovery, and prior funding rounds included support from investors such as Polaris Partners, ClavystBio, Invus, EDBI, Coronet Ventures, SEEDS Capital, Baidu Ventures, WuXi AppTec, Pavilion Capital and WI Harper. |
| Jun 2026 | Undisclosed stage | Pfizer Venture Investments (lead) | - | - | - |
| Feb 2026 | Undisclosed stage | - | $14M | - | Engine Biosciences is a Singapore- and Silicon Valley-based precision oncology biotech company focused on developing targeted cancer medicines and biomarkers for patient selection. The company's platform includes NetMAPPR, a proprietary machine learning network biology platform, and CombiGEM, a combinatorial genetics system designed to advance drug discovery and development. In a Series A extension round, Engine Biosciences secured $27 million in additional funding, bringing the total Series A round to $70 million and total funds raised to $86 million. The financing was led by Polaris Partners, with participation from existing investors ClavystBio, Invus, and EDBI, as well as new investors Coronet Ventures and SEEDS Capital (investment arm of Enterprise Singapore). The company plans to use the capital to advance its biomarker and target discoveries toward clinical settings through internal development, collaborations, and strategic partnerships. Engine's programs are underpinned by an extensive patent portfolio in precision medicine. |
| Oct 2023 | Series A | Polaris Partners (lead); Seeds Capital; Invus; ClavystBio; Coronet Ventures; EDBI | $27M | - | Engine Biosciences is a Singapore- and Silicon Valley-based biotech company that leverages machine learning and high-throughput biology, including its proprietary NetMAPPR network biology platform and CombiGEM combinatorial genetics system, to discover and develop precision oncology medicines and novel biomarkers for patient selection. The company announced a $27 million Series A extension in late 2023, led by Polaris Partners, with participation from new investors Coronet Ventures and Seeds Capital, as well as existing investors ClavystBio, Invus, and EDBI, bringing the total Series A to $70 million (or $43 million in some reports) and aggregate funding since inception to $86 million. Wen Qi Ho, Ph.D., from ClavystBio, joined the board in conjunction with the financing. The funds are earmarked to advance biomarker and target discoveries toward the clinic via internal development, collaborations, and partnerships, including progressing precision oncology programs like ENB-812, a PKMYT1 synthetic lethal target with novel biomarkers identified since 2019, through preclinical proof-of-concept, lead optimization, and regulatory approvals for clinical trials. Engine has revealed over 30 previously unidentified precision medicine opportunities with validation data, advanced multiple internal drug discovery programs, and identified biomarkers that sensitize tumors by 100 times to specific clinical-stage investigational drugs, enhancing clinical outcomes and drug development economics. The company's extensive patent portfolio underpins its platform and programs. Investors highlighted Engine's progress in translating technologies into compelling precision medicines, with quotes from Amy Schulman of Polaris Partners emphasizing clinical value creation and Nirdesh Gupta of Coronet Ventures noting alignment with precision medicine breakthroughs and Singapore's global potential. |
| Oct 2023 | Series A | - | $5M | - | Engine Biosciences, a Singapore- and Silicon Valley-based biotech company, pioneers network biomedicine using proprietary technologies like the NetMAPPR machine learning platform and CombiGEM combinatorial genetics system for drug discovery and cellular reprogramming. The company focuses on precision oncology therapeutics, biomarker discovery, and advancing programs toward clinical settings through internal development and partnerships. On October 3, 2023, Engine Biosciences completed a Series A - III funding round raising $9 million, contributing to its total funding of $80 million across five rounds. Earlier in November 2023, it secured a $27 million Series A extension led by Polaris Partners, with participation from ClavystBio, Invus, EDBI, Coronet Ventures, and SEEDS Capital, bringing the total Series A to $70 million and overall funds raised to $86 million. The extension supports preclinical studies, regulatory approvals for clinical trials, and pharmaceutical partnerships. Engine Biosciences applies its platform across disease indications including cancer, leveraging high-throughput wet lab experimentation and AI algorithms to accelerate R&D for new therapies. Previous rounds include a $43 million Series A in May 2021 led by Polaris Partners and a $10 million seed in 2018. |
| Jul 2023 | Series A | Polaris Partners; EDBI | $18M | $82M | Engine Biosciences, a Singapore- and US-based biotech leveraging machine learning and high-throughput biology via its NetMAPPR platform, raised an oversubscribed S$57 million (~$43 million USD) Series A round led by Polaris Partners, with participation from EDBI and other existing and new investors including Invus Group. Funds will expand its precision oncology therapeutics portfolio, prepare first clinical programs, scale the platform, and double headcount to 60 by year-end. The company differentiates through efficient identification of disease-driving genetic errors and large-scale therapeutic testing, progressing novel biology into drug discovery programs and small molecule inhibitors for liver, ovarian, colorectal, and breast cancers—responsible for 2.5 million annual deaths. This initial Series A built on prior funding, with a $27 million extension later in 2023 led by Polaris Partners and EDBI among others, bringing total Series A to ~$70 million and cumulative funding to $86 million since 2016 inception. Engine has revealed over 30 precision medicine opportunities with validation, advanced internal programs like ENB-812 targeting PKMYT1 synthetic lethality across tumor types with preclinical proof-of-concept, and maintains an extensive patent portfolio. New funds from the extension support biomarker/target advancement to clinic, preclinical studies, regulatory approvals, and pharma partnerships. |
| May 2021 | Series A | Polaris Partners (lead); Wuxi AppTec; Invus; Baidu Ventures; Goodman Capital; Vectr Ventures; DHVC; EDBI; Nest.Bio Ventures; WI Harper Group; 6 Dimensions Capital | $43M | - | Engine Biosciences is a Singapore and San Francisco-based biotech company founded in 2016 that applies machine learning and large-scale biology testing to discover precision medicine-based therapies for cancer and other diseases. The company's proprietary platform combines advanced computational tools with combinatorial genetics to decipher complex biology and identify novel drug targets and therapeutic opportunities for genetically-defined patient populations. In May 2021, Engine Biosciences completed an oversubscribed Series A funding round that raised $43 million led by US-based Polaris Partners, with participation from new investors Invus Group and existing investors including 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio. The round valued the company at approximately US$82 million post-money valuation, bringing total funding raised to date to S$70 million (approximately $52 million USD equivalent). Engine's pipeline focused on precision oncology includes programs with evidence of efficacy in treating liver, ovarian, colorectal, and breast cancers, which collectively account for approximately 2.5 million deaths annually. The company planned to use the new capital to expand its portfolio of precision oncology therapeutics, prepare for first clinical programs, and scale its proprietary technology platform. Post-funding, Engine announced plans to double its headcount to approximately 60 employees by the end of 2022, with focus on expanding machine learning, laboratory, and chemistry teams. |
| Jan 2018 | Seed | 6 Dimensions Capital (lead); DHVC (lead); Wuxi AppTec; Baidu Ventures; Goodman Capital; EDBI; Nest.Bio Ventures; WI Harper Group | $10M | - | Engine Biosciences, a Singapore- and Silicon Valley-based biotech company, raised $10 million in an oversubscribed seed financing round in January 2018, the largest institutional seed financing recorded in Southeast Asia at the time. The round was co-led by DHVC (Danhua Capital) and 6 Dimensions Capital, with participation from WuXi AppTec, EDBI, Pavilion Capital (a Temasek subsidiary), Baidu Ventures, WI Harper, and Nest.Bio Ventures. The funds supported building its AI and genomics network biomedicine platform for faster drug discovery, as well as expanding its scientific and executive team. Engine Biosciences pioneers an artificial intelligence and genomics platform to address complex biological processes in cells, aiming to reduce high failure rates in drug development by generating novel data and insights. The platform integrates data science, machine learning, high-throughput biology, and combinatorial genetics to uncover gene interactions and biological networks underlying diseases more efficiently than traditional methods. Investors highlighted the platform's potential to provide insights into complex disease pathways previously unattainable with conventional research. |
Who has invested in Engine Biosciences?
16 investors have backed Engine Biosciences across its funding rounds, including EDBI, Polaris Partners, Invus, Baidu Ventures, DHVC and WI Harper Group.
Lead investors include GV, Pfizer Venture Investments, Polaris Partners, 6 Dimensions Capital and DHVC.
Engine Biosciences Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| Singapore | 4 | Participant | Jan 2018 | |
 Boston, MA | 3 | Lead | May 2021 | |
 Shanghai | 2 | Participant | Jan 2018 | |
| New York City, NY | 2 | Participant | May 2021 | |
| Beijing | 2 | Participant | Jan 2018 | |
| New York City, NY | 2 | Participant | Jan 2018 | |
| San Francisco, CA | 2 | Lead | Jan 2018 | |
| Boston, MA | 2 | Participant | Jan 2018 | |
| San Francisco, CA | 2 | Participant | Jan 2018 | |
| China | 2 | Lead | Jan 2018 | |
| New York City, NY | 1 | Lead | Jun 2026 | |
| Singapore | 1 | Participant | Oct 2023 | |
| San Francisco, CA | 1 | Lead | Aug 2026 | |
This data is available for Pro users. Sign up to see all 16 Engine Biosciences investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialEngine Biosciences Competitors
Engine Biosciences competitors include listed companies like M1 Aesthetics and Laboratorios Richmond, and private ones like RedShift BioAnalytics, PreOmics, Kytopen and Yipscell.
| Company | HQ | Status | Revenue | EBITDA | Valuation |
|---|---|---|---|---|---|
| United States | Private | - | - | $88M | |
 Munich | Private | - | - | $71M | |
| Germany | Publicly listed | $286M | $13M | $71M | |
| United States | Private | - | - | $70M | |
 South Korea | Private | - | - | $69M | |
 Argentina | Publicly listed | $84M | $22M | $81M |
Engine Biosciences Public Comps
Engine Biosciences is still privately-owned, but its public comps include Laboratorios Richmond, Connect Biopharma, Dicot Pharma, Fortress Biotech, Adocia, Aldeyra Therapeutics, Intercure, Adicet Bio, Bioton and Zomedica.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $84M | $22M | 2.9x | - | 10.8x | - | |||
| $64K | ($57M) | 781.7x | 9.3x | (0.9x) | - | |||
| - | ($8M) | - | - | (6.9x) | - | |||
| $63M | ($23M) | - | - | - | - | |||
| $2M | ($18M) | 43.7x | 5.7x | (4.2x) | (14.6x) | |||
| - | ($35M) | - | - | (1.1x) | - | |||
| $89M | ($3M) | 1.4x | - | (42.0x) | - | |||
| - | ($116M) | - | - | - | - | |||
This data is available for Pro users. Sign up to see all Engine Biosciences competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Engine Biosciences
| When was Engine Biosciences founded? | Engine Biosciences was founded in 2014. |
| Where is Engine Biosciences headquartered? | Engine Biosciences is headquartered in Singapore, Singapore. |
| Is Engine Biosciences publicly listed? | No, Engine Biosciences is a private, VC-backed company. |
| What is Engine Biosciences' valuation? | Engine Biosciences was last valued at $82M in its Series A in July 2023. |
| How much funding has Engine Biosciences raised? | Engine Biosciences has raised $122M across 8 funding rounds. |
| What was Engine Biosciences' last funding round? | Engine Biosciences' last funding round was a $5M undisclosed-stage round in August 2026, led by GV. |
| Who are Engine Biosciences' investors? | Engine Biosciences' investors include EDBI, Polaris Partners, Wuxi AppTec, Invus, Baidu Ventures, Goodman Capital, DHVC, Nest.Bio Ventures, WI Harper Group, 6 Dimensions Capital and 6 others. |
| Which companies are comparable to Engine Biosciences? | Companies comparable to Engine Biosciences include RedShift BioAnalytics, PreOmics, M1 Aesthetics, Kytopen, Yipscell and Laboratorios Richmond. |
See companies similar to Engine Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.